메뉴 건너뛰기




Volumn 12, Issue 8, 2008, Pages 969-979

Signaling through CD80: An approach for treating lymphomas

Author keywords

Cancer; CD80; Costimulation; Immunotherapy; Lymphomas; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; B7 ANTIGEN; BEVACIZUMAB; CANCER VACCINE; CASPASE 8; CD28 ANTIGEN; CD86 ANTIGEN; CETUXIMAB; CYTOKINE; DOXORUBICIN; FLUDARABINE; GALIXIMAB; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELPHALAN; MITOMYCIN C; MONOCLONAL ANTIBODY; PLACEBO; PROTEIN BAX; RITUXIMAB; STAPHYLOCOCCUS ENTEROTOXIN A; STREPTAVIDIN; TRASTUZUMAB;

EID: 48449102012     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.8.969     Document Type: Review
Times cited : (23)

References (80)
  • 1
    • 33646568784 scopus 로고    scopus 로고
    • Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
    • Kamangar F, Dores GM, Anderson W. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50
    • (2006) J Clin Oncol , vol.24 , pp. 2137-2150
    • Kamangar, F.1    Dores, G.M.2    Anderson, W.3
  • 2
    • 0034921235 scopus 로고    scopus 로고
    • The expanding world of co-stimulation: The two-signal model revisited
    • Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. Trends Immunol 2001;22:217-23
    • (2001) Trends Immunol , vol.22 , pp. 217-223
    • Chambers, C.A.1
  • 3
    • 0034596948 scopus 로고    scopus 로고
    • Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
    • Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34
    • (2000) J Exp Med , vol.192 , pp. 1027-1034
    • Freeman, G.J.1    Long, A.J.2    Iwai, Y.3
  • 4
    • 0026567027 scopus 로고
    • The role of cell division in the induction of clonal anergy
    • Jenkins MK. The role of cell division in the induction of clonal anergy. Immunol Today 1992;13:69-73
    • (1992) Immunol Today , vol.13 , pp. 69-73
    • Jenkins, M.K.1
  • 5
    • 0036170440 scopus 로고    scopus 로고
    • Activation and inhibition of lymphocytes by costimulation
    • Frauwirth KA, Thompson CB. Activation and inhibition of lymphocytes by costimulation. J Clin Invest 2002;109:295-309
    • (2002) J Clin Invest , vol.109 , pp. 295-309
    • Frauwirth, K.A.1    Thompson, C.B.2
  • 6
    • 41649102470 scopus 로고    scopus 로고
    • Influence of CD80 and CD86 co-stimulation in the modulation of the activation of antigen presenting cells
    • Manzoor A Mir, Javed N Agrewala. Influence of CD80 and CD86 co-stimulation in the modulation of the activation of antigen presenting cells. Curr Immunol Rev 2007;3:160-9
    • (2007) Curr Immunol Rev , vol.3 , pp. 160-169
    • Mir, M.A.1    Agrewala, J.N.2
  • 7
    • 0036852170 scopus 로고    scopus 로고
    • CTLA-4-Ig regulates tryptophan catabolism in vivo
    • Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097-101
    • (2002) Nat Immunol , vol.3 , pp. 1097-1101
    • Grohmann, U.1    Orabona, C.2    Fallarino, F.3
  • 8
    • 34748835898 scopus 로고    scopus 로고
    • IDO and regulatory T cells: A role for reverse signalling and non-canonical NFκB activation [review]
    • Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NFκB activation [review]. Nat Rev Immunol 2007;7:817-23
    • (2007) Nat Rev Immunol , vol.7 , pp. 817-823
    • Puccetti, P.1    Grohmann, U.2
  • 9
    • 21044458270 scopus 로고    scopus 로고
    • Cutting edge: Silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant
    • Orabona C, Belladonna ML, Vacca C, et al. Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol 2005;174:6582-6
    • (2005) J Immunol , vol.174 , pp. 6582-6586
    • Orabona, C.1    Belladonna, M.L.2    Vacca, C.3
  • 10
    • 33645129040 scopus 로고    scopus 로고
    • Emerging drugs for chronic lymphocytic leukaemia
    • Yee KW, O'Brien SM. Emerging drugs for chronic lymphocytic leukaemia. Expert Opin Emerging Drugs 2006;11:167-89
    • (2006) Expert Opin Emerging Drugs , vol.11 , pp. 167-189
    • Yee, K.W.1    O'Brien, S.M.2
  • 11
    • 0037040863 scopus 로고    scopus 로고
    • Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma
    • Suvas S, Singh V, Sahdev S, et al. Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002;277:7766-75
    • (2002) J Biol Chem , vol.277 , pp. 7766-7775
    • Suvas, S.1    Singh, V.2    Sahdev, S.3
  • 12
    • 0029896194 scopus 로고    scopus 로고
    • Transmembrane signaling through CD80 B7-1 induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation
    • Hirokawa M, Kuroki J, Kitabayashi A, Miura AB. Transmembrane signaling through CD80 B7-1 induces growth arrest and cell spreading of human B lymphocytes accompanied by protein tyrosine phosphorylation. Immunol Lett 1996;50:95-8
    • (1996) Immunol Lett , vol.50 , pp. 95-98
    • Hirokawa, M.1    Kuroki, J.2    Kitabayashi, A.3    Miura, A.B.4
  • 13
    • 22344436992 scopus 로고    scopus 로고
    • Phase I/II study of galiximab, an antt-CD80 antibody, for relapsed or refractory follicular lymphoma
    • Czuczman MS, Thall A, Witzig TE, et al. Phase I/II study of galiximab, an antt-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005;23:4390-8
    • (2005) J Clin Oncol , vol.23 , pp. 4390-4398
    • Czuczman, M.S.1    Thall, A.2    Witzig, T.E.3
  • 14
    • 34547844167 scopus 로고    scopus 로고
    • Leonard J, Friedberg J, Younes A, et al. A phase I/II study of galiximab an anti-CD80 monoclonal antibody in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;29. Ann Oncol 2007;18:1216-23
    • Leonard J, Friedberg J, Younes A, et al. A phase I/II study of galiximab an anti-CD80 monoclonal antibody in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;29. Ann Oncol 2007;18:1216-23
  • 15
    • 2942674463 scopus 로고    scopus 로고
    • Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses
    • Wang S, Chen L. Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes Infect 2004;6:759-66
    • (2004) Microbes Infect , vol.6 , pp. 759-766
    • Wang, S.1    Chen, L.2
  • 16
    • 0033565764 scopus 로고    scopus 로고
    • Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: Lessons from recurrent tumors
    • Zheng P, Sarma S, Guo Y, Liu Y. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res 1999;59:3461-7
    • (1999) Cancer Res , vol.59 , pp. 3461-3467
    • Zheng, P.1    Sarma, S.2    Guo, Y.3    Liu, Y.4
  • 17
    • 0028952046 scopus 로고
    • Role of B7-1 in mediating an immune response to myeloid leukemia cells
    • Matulonis UA, Dosiou C, Lamont C, et al. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995;85:2507-15
    • (1995) Blood , vol.85 , pp. 2507-2515
    • Matulonis, U.A.1    Dosiou, C.2    Lamont, C.3
  • 18
    • 0028343870 scopus 로고
    • T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: An important role of B7/ BB1 in the induction, recruitment, and effector function of antitumor T cells
    • Ramarathinam L, Castle M, WU Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/ BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994;179:1205-14
    • (1994) J Exp Med , vol.179 , pp. 1205-1214
    • Ramarathinam, L.1    Castle, M.2    WU, Y.3    Liu, Y.4
  • 19
    • 0029864363 scopus 로고    scopus 로고
    • Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
    • Huang AY, Bruce AT, Pardoll DM, Levitsky HI. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 1996;183:769-76
    • (1996) J Exp Med , vol.183 , pp. 769-776
    • Huang, A.Y.1    Bruce, A.T.2    Pardoll, D.M.3    Levitsky, H.I.4
  • 20
    • 0028861977 scopus 로고
    • A reassessment of the role of B7-1 expression in tumor rejection
    • WU TC, Huang AY, Jaffee EM, et al. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995;182:1415-21
    • (1995) J Exp Med , vol.182 , pp. 1415-1421
    • WU, T.C.1    Huang, A.Y.2    Jaffee, E.M.3
  • 21
    • 33747803052 scopus 로고    scopus 로고
    • CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion
    • Xia D, Hao S, Xiang J. CD8+ cytotoxic T-APC stimulate central memory CD8+ T cell responses via acquired peptide-MHC class I complexes and CD80 costimulation, and IL-2 secretion. J Immunol 2006;177:2976-84
    • (2006) J Immunol , vol.177 , pp. 2976-2984
    • Xia, D.1    Hao, S.2    Xiang, J.3
  • 22
    • 0035889949 scopus 로고    scopus 로고
    • Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory
    • Suresh M, Whitmire JK, Harrington LE, et al. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol 2001;167:5565-73
    • (2001) J Immunol , vol.167 , pp. 5565-5573
    • Suresh, M.1    Whitmire, J.K.2    Harrington, L.E.3
  • 23
    • 0033384806 scopus 로고    scopus 로고
    • The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia
    • Matsumoto K, Anasetti C. The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia. Leuk Lymphoma 1999;35:427-35
    • (1999) Leuk Lymphoma , vol.35 , pp. 427-435
    • Matsumoto, K.1    Anasetti, C.2
  • 24
    • 0030026868 scopus 로고    scopus 로고
    • B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro
    • Gajewski TF. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J Immunol 1996;156:465-72
    • (1996) J Immunol , vol.156 , pp. 465-472
    • Gajewski, T.F.1
  • 25
    • 0032534599 scopus 로고    scopus 로고
    • Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells
    • La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells. J Immunol 1998;161:6552-8
    • (1998) J Immunol , vol.161 , pp. 6552-6558
    • La Motte, R.N.1    Sharpe, A.H.2    Bluestone, J.A.3    Mokyr, M.B.4
  • 26
    • 0027451433 scopus 로고
    • B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance
    • Boussiotis VA, Freeman GJ, Gray G, et al. B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance. J Exp Med 1993;178:1753-63
    • (1993) J Exp Med , vol.178 , pp. 1753-1763
    • Boussiotis, V.A.1    Freeman, G.J.2    Gray, G.3
  • 27
    • 0026543202 scopus 로고
    • Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex
    • Reiser H, Freeman GJ, Razi-Wolf Z, et al. Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci USA 1992;89:271-5
    • (1992) Proc Natl Acad Sci USA , vol.89 , pp. 271-275
    • Reiser, H.1    Freeman, G.J.2    Razi-Wolf, Z.3
  • 28
    • 0027175221 scopus 로고    scopus 로고
    • Harding FA, Allison JP CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993;177:1791-6
    • Harding FA, Allison JP CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993;177:1791-6
  • 30
    • 0027392843 scopus 로고
    • Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells
    • Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993;259:368-70
    • (1993) Science , vol.259 , pp. 368-370
    • Townsend, S.E.1    Allison, J.P.2
  • 31
    • 33644520242 scopus 로고    scopus 로고
    • Low surface expression of B7-1 CD80 is an immunoescape mechanism of colon carcinoma
    • Tirapu I, Huarte E, Guiducci C, et al. Low surface expression of B7-1 CD80 is an immunoescape mechanism of colon carcinoma. Cancer Res 2006;66:2442-50
    • (2006) Cancer Res , vol.66 , pp. 2442-2450
    • Tirapu, I.1    Huarte, E.2    Guiducci, C.3
  • 32
    • 0036569402 scopus 로고    scopus 로고
    • A role for IFN-γ in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo
    • Kelly JM, Takeda K, Darcy PK, et al. A role for IFN-γ in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 2002;168:4472-9
    • (2002) J Immunol , vol.168 , pp. 4472-4479
    • Kelly, J.M.1    Takeda, K.2    Darcy, P.K.3
  • 33
    • 0030273745 scopus 로고    scopus 로고
    • Triggering of natural killer cells by the costimulatory molecule CD80 B7-1
    • Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells by the costimulatory molecule CD80 B7-1. Immunity 1996;5:311-7
    • (1996) Immunity , vol.5 , pp. 311-317
    • Chambers, B.J.1    Salcedo, M.2    Ljunggren, H.G.3
  • 34
    • 0344737668 scopus 로고    scopus 로고
    • Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells
    • Gao JX, Liu X, Wen J, et al. Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells. Blood 2003;102:4456-63
    • (2003) Blood , vol.102 , pp. 4456-4463
    • Gao, J.X.1    Liu, X.2    Wen, J.3
  • 35
    • 0035106024 scopus 로고    scopus 로고
    • B7.1 expression eliminates tumor resistance to IL-12 gene therapy
    • Heise CP, Shi F, Albertini MR, Mahvi DM. B7.1 expression eliminates tumor resistance to IL-12 gene therapy. Cancer Gene Ther 2001;8:118-27
    • (2001) Cancer Gene Ther , vol.8 , pp. 118-127
    • Heise, C.P.1    Shi, F.2    Albertini, M.R.3    Mahvi, D.M.4
  • 36
    • 0029070142 scopus 로고
    • Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity
    • Geldhof AB, Raes G, Bakkus M, et al. Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res 1995;55:2730-3
    • (1995) Cancer Res , vol.55 , pp. 2730-2733
    • Geldhof, A.B.1    Raes, G.2    Bakkus, M.3
  • 37
    • 0027078670 scopus 로고
    • Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
    • Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102
    • (1992) Cell , vol.71 , pp. 1093-1102
    • Chen, L.1    Ashe, S.2    Brady, W.A.3
  • 38
    • 0027211058 scopus 로고
    • Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules
    • Baskar S, Ostrand-Rosenberg S, Nabavi N, et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 1993;90:5687-90
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 5687-5690
    • Baskar, S.1    Ostrand-Rosenberg, S.2    Nabavi, N.3
  • 39
    • 7444229121 scopus 로고    scopus 로고
    • Usefulness of inhibiting the lymph node metastasis in human gastric carcinoma by B71 gene transfection
    • Sakate Y, Yashiro M, Tanaka H, et al. Usefulness of inhibiting the lymph node metastasis in human gastric carcinoma by B71 gene transfection. J Surg Res 2004;122:89-95
    • (2004) J Surg Res , vol.122 , pp. 89-95
    • Sakate, Y.1    Yashiro, M.2    Tanaka, H.3
  • 40
    • 0031839501 scopus 로고    scopus 로고
    • The role of B7-CD28 co-stimulation in tumor rejection
    • Yu X, Abe R, Hodes RJ. The role of B7-CD28 co-stimulation in tumor rejection. Int Immunol 1998;10:791-7
    • (1998) Int Immunol , vol.10 , pp. 791-797
    • Yu, X.1    Abe, R.2    Hodes, R.J.3
  • 41
    • 0037089410 scopus 로고    scopus 로고
    • B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo
    • Bai XF, Liu J, May KF Jr, et al. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo. Blood 2002;99:2880-9
    • (2002) Blood , vol.99 , pp. 2880-2889
    • Bai, X.F.1    Liu, J.2    May Jr, K.F.3
  • 42
    • 0028223557 scopus 로고
    • T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector
    • Dohring C, Angman L, Spagnoli G, Lanzavecchia A. T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer 1994;57:754-9
    • (1994) Int J Cancer , vol.57 , pp. 754-759
    • Dohring, C.1    Angman, L.2    Spagnoli, G.3    Lanzavecchia, A.4
  • 43
    • 0028853546 scopus 로고
    • A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes
    • Sule-Suso J, Arienti F, Melani C, et al. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Eur J Immunol 1995;25:2737-42
    • (1995) Eur J Immunol , vol.25 , pp. 2737-2742
    • Sule-Suso, J.1    Arienti, F.2    Melani, C.3
  • 44
    • 0033682056 scopus 로고    scopus 로고
    • + immunoregulatory T cells that control autoimmune diabetes
    • + immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-40
    • (2000) Immunity , vol.12 , pp. 431-440
    • Salomon, B.1    Lenschow, D.J.2    Rhee, L.3
  • 45
    • 0034660469 scopus 로고    scopus 로고
    • Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells
    • Sojka DK, Donepudi M, Bluestone JA, Mokyr MB. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 2000;164:6230-6
    • (2000) J Immunol , vol.164 , pp. 6230-6236
    • Sojka, D.K.1    Donepudi, M.2    Bluestone, J.A.3    Mokyr, M.B.4
  • 46
    • 0037810672 scopus 로고    scopus 로고
    • The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens
    • Lohr J, Knoechel B, Jiang S, et al. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol 2003;4:664-9
    • (2003) Nat Immunol , vol.4 , pp. 664-669
    • Lohr, J.1    Knoechel, B.2    Jiang, S.3
  • 47
    • 14944375827 scopus 로고    scopus 로고
    • Dendritic cells giveth and taketh away
    • Abbas AK, Sharpe AH. Dendritic cells giveth and taketh away. Nat Immunol 2005;6:227-8
    • (2005) Nat Immunol , vol.6 , pp. 227-228
    • Abbas, A.K.1    Sharpe, A.H.2
  • 48
    • 33645450748 scopus 로고    scopus 로고
    • Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo
    • Singh NP, Miller RW, Yolcu ES, et al. Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo. Hum Gene Ther 2006;17:334-46
    • (2006) Hum Gene Ther , vol.17 , pp. 334-346
    • Singh, N.P.1    Miller, R.W.2    Yolcu, E.S.3
  • 49
    • 33748880457 scopus 로고    scopus 로고
    • The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery
    • Liu J, Xia X, Torrero M, et al. The mechanism of exogenous B7.1-enhanced IL-12-mediated complete regression of tumors by a single electroporation delivery. Int J Cancer 2006;119:2113-8
    • (2006) Int J Cancer , vol.119 , pp. 2113-2118
    • Liu, J.1    Xia, X.2    Torrero, M.3
  • 50
    • 0036230069 scopus 로고    scopus 로고
    • Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: Antitumor efficacy and immunoregulation in a nonimmunogenic tumor model
    • Putzer BM, Rodicker F, Hitt MM, et al. Improved treatment of pancreatic cancer by IL-12 and B7.1 costimulation: antitumor efficacy and immunoregulation in a nonimmunogenic tumor model. Mol Ther 2002;5:405-12
    • (2002) Mol Ther , vol.5 , pp. 405-412
    • Putzer, B.M.1    Rodicker, F.2    Hitt, M.M.3
  • 51
    • 0029101821 scopus 로고
    • Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines
    • Cayeux S, Beck C, Aicher A, et al. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 1995;25:2325-31
    • (1995) Eur J Immunol , vol.25 , pp. 2325-2331
    • Cayeux, S.1    Beck, C.2    Aicher, A.3
  • 52
    • 33745740342 scopus 로고    scopus 로고
    • Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity
    • Si SY, Hu PZ, Huang YY, et al. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity. Biochem Biophys Res Commun 2006;347:208-14
    • (2006) Biochem Biophys Res Commun , vol.347 , pp. 208-214
    • Si, S.Y.1    Hu, P.Z.2    Huang, Y.Y.3
  • 53
    • 0033870234 scopus 로고    scopus 로고
    • B7-1, IFNγ and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma
    • Van Ginderachter JA, Liu Y, Geldhof AB, et al. B7-1, IFNγ and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma. Int J Cancer 2000;87:539-47
    • (2000) Int J Cancer , vol.87 , pp. 539-547
    • Van Ginderachter, J.A.1    Liu, Y.2    Geldhof, A.B.3
  • 54
    • 0028898598 scopus 로고
    • Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice
    • Baskar S, Glimcher L, Nabavi N, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995;181:619-29
    • (1995) J Exp Med , vol.181 , pp. 619-629
    • Baskar, S.1    Glimcher, L.2    Nabavi, N.3
  • 55
    • 0037259316 scopus 로고    scopus 로고
    • Transfection of B7-1 cDNA empowers antigen presentation of blood malignant cells for activation of anti-tumor T cells
    • Ke X, Jia L, Wang J, Wang D. Transfection of B7-1 cDNA empowers antigen presentation of blood malignant cells for activation of anti-tumor T cells. Chin Med J Engl 2003;116:78-84
    • (2003) Chin Med J Engl , vol.116 , pp. 78-84
    • Ke, X.1    Jia, L.2    Wang, J.3    Wang, D.4
  • 56
    • 10944238100 scopus 로고    scopus 로고
    • IL-2/B7.1 CD80 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: A strategy to generate whole cell vaccines for AML
    • Chan L, Hardwick N, Darling D, et al. IL-2/B7.1 CD80 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther 2005;11:120-31
    • (2005) Mol Ther , vol.11 , pp. 120-131
    • Chan, L.1    Hardwick, N.2    Darling, D.3
  • 57
    • 0036223749 scopus 로고    scopus 로고
    • Phase I trial of a B7-1 CD80 gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma
    • Antonia Sj, Seigne J, Diaz J, et al. Phase I trial of a B7-1 CD80 gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 2002;167:1995-2000
    • (2002) J Urol , vol.167 , pp. 1995-2000
    • Antonia, S.1    Seigne, J.2    Diaz, J.3
  • 58
    • 0034920504 scopus 로고    scopus 로고
    • Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma
    • Wen XY, Mandelbaum S, Li ZH, et al. Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther 2001;8:361-70
    • (2001) Cancer Gene Ther , vol.8 , pp. 361-370
    • Wen, X.Y.1    Mandelbaum, S.2    Li, Z.H.3
  • 59
    • 0037616155 scopus 로고    scopus 로고
    • Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses
    • Carlring J, Shaif-Muthana M, Sisley K, et al. Apoptotic cell death in conjunction with CD80 costimulation confers uveal melanoma cells with the ability to induce immune responses. Immunology 2003;109:41-8
    • (2003) Immunology , vol.109 , pp. 41-48
    • Carlring, J.1    Shaif-Muthana, M.2    Sisley, K.3
  • 60
    • 0036320834 scopus 로고    scopus 로고
    • Activation of caspase-3 alone is insufficient for apoptotic morphological changes in human neuroblastoma cells
    • Racke Mm, Mosior M, Kovacevic S. Activation of caspase-3 alone is insufficient for apoptotic morphological changes in human neuroblastoma cells. J Neurochem 2002;80:1039-48
    • (2002) J Neurochem , vol.80 , pp. 1039-1048
    • Racke, M.1    Mosior, M.2    Kovacevic, S.3
  • 61
    • 0034667357 scopus 로고    scopus 로고
    • Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program
    • Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A. Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 2000;60:5673-80
    • (2000) Cancer Res , vol.60 , pp. 5673-5680
    • Ruiz-Ruiz, C.1    Munoz-Pinedo, C.2    Lopez-Rivas, A.3
  • 62
    • 0028791059 scopus 로고
    • Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
    • Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-8
    • (1995) Science , vol.270 , pp. 985-988
    • Waterhouse, P.1    Penninger, J.M.2    Timms, E.3
  • 63
    • 33747821753 scopus 로고    scopus 로고
    • Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells
    • Bogner C, Sandherr M, Perker M, et al. Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells. Ann Hematol 2006;85:458-62
    • (2006) Ann Hematol , vol.85 , pp. 458-462
    • Bogner, C.1    Sandherr, M.2    Perker, M.3
  • 64
    • 9244247370 scopus 로고    scopus 로고
    • CD28-B7 bidirectional signaling: A two-way street to activation
    • Logue EC, Sha WC. CD28-B7 bidirectional signaling: a two-way street to activation. Nat Immunol 2004;5:1103-5
    • (2004) Nat Immunol , vol.5 , pp. 1103-1105
    • Logue, E.C.1    Sha, W.C.2
  • 65
    • 9244231842 scopus 로고    scopus 로고
    • CD28 induces immuno-stimulatory signals in dendritic cells via CD80 and CD86
    • Orabona C, Grohmann U, Belladonna ML, et al. CD28 induces immuno-stimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004;5:1134-42
    • (2004) Nat Immunol , vol.5 , pp. 1134-1142
    • Orabona, C.1    Grohmann, U.2    Belladonna, M.L.3
  • 66
    • 2142714017 scopus 로고    scopus 로고
    • Monoclonal antibodies as therapeutic agents for cancer [review]
    • Harris M. Monoclonal antibodies as therapeutic agents for cancer [review]. Lancet Oncol 2004;5(5):292-302
    • (2004) Lancet Oncol , vol.5 , Issue.5 , pp. 292-302
    • Harris, M.1
  • 67
    • 0037092951 scopus 로고    scopus 로고
    • Therapeutic role of alemtuzumab (campath H1) in patients who have failed fludarabine: Results of a large international study
    • Keating M, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (campath H1) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61
    • (2002) Blood , vol.99 , pp. 3554-3561
    • Keating, M.1    Flinn, I.2    Jain, V.3
  • 68
    • 0043177668 scopus 로고    scopus 로고
    • Bevacizumab a monoclonal antibody to vascular-endothelial growth factor prolongs survival in first-line colorectal cancer: Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5 fluorouracil, leucovorin) as first-line therapy in subjects with metastatic colorectal cancer [abstract 3646]
    • Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab a monoclonal antibody to vascular-endothelial growth factor prolongs survival in first-line colorectal cancer: results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5 fluorouracil, leucovorin) as first-line therapy in subjects with metastatic colorectal cancer [abstract 3646]. Proc Am Soc Clin Oncol 2003;22
    • (2003) Proc Am Soc Clin Oncol , pp. 22
    • Hurwitz, H.1    Fehrenbacher, L.2    Cartwright, T.3
  • 69
    • 0037251878 scopus 로고    scopus 로고
    • Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia [review]
    • Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia [review]. Drugs 2003;63:803-43
    • (2003) Drugs , vol.63 , pp. 803-843
    • Plosker, G.L.1    Figgitt, D.P.2
  • 70
    • 0030800131 scopus 로고    scopus 로고
    • Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
    • Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-85
    • (1997) Cancer Biother Radiopharm , vol.12 , pp. 177-185
    • Demidem, A.1    Lam, T.2    Alas, S.3
  • 71
    • 0033855660 scopus 로고    scopus 로고
    • Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
    • Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43
    • (2000) J Clin Oncol , vol.18 , pp. 3135-3143
    • Davis, T.A.1    Grillo-López, A.J.2    White, C.A.3
  • 72
    • 48449095747 scopus 로고    scopus 로고
    • IDEC Pharmaceuticals. Rituxan (rituximab) package insert. San Diego, CA, IDEC Pharmaceuticals Corporation; 2002
    • IDEC Pharmaceuticals. Rituxan (rituximab) package insert. San Diego, CA, IDEC Pharmaceuticals Corporation; 2002
  • 73
    • 0345604387 scopus 로고    scopus 로고
    • Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma
    • Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:2402-9
    • (2003) Cancer , vol.98 , pp. 2402-2409
    • Lyman, G.H.1    Delgado, D.J.2
  • 74
    • 48449083215 scopus 로고    scopus 로고
    • Genentech, Inc. Herceptin (trastuzumab) package insert. South San Francisco, CA, Genentech, Inc, 2003
    • Genentech, Inc. Herceptin (trastuzumab) package insert. South San Francisco, CA, Genentech, Inc.; 2003
  • 75
    • 0028568292 scopus 로고
    • Immunoglobulin fold characteristics of B7-1 CD80 and B7-2 CD86
    • Bajorath J, Peach RJ, Linsley PS. Immunoglobulin fold characteristics of B7-1 CD80 and B7-2 CD86. Protein Sci 1994;3:2148-50
    • (1994) Protein Sci , vol.3 , pp. 2148-2150
    • Bajorath, J.1    Peach, R.J.2    Linsley, P.S.3
  • 76
    • 1642295729 scopus 로고    scopus 로고
    • Novel therapies for chronic lymphocytic leukemia
    • Mavromatis BH, Cheson BD. Novel therapies for chronic lymphocytic leukemia. Blood Rev 2004;18:137-48
    • (2004) Blood Rev , vol.18 , pp. 137-148
    • Mavromatis, B.H.1    Cheson, B.D.2
  • 77
    • 48449092834 scopus 로고    scopus 로고
    • Anti-CD80 monoclonal antibody: Galiximab
    • Czuczman MS. Anti-CD80 monoclonal antibody: galiximab. Haematol Rep 2005;36:35-6
    • (2005) Haematol Rep , vol.36 , pp. 35-36
    • Czuczman, M.S.1
  • 78
    • 1842735276 scopus 로고    scopus 로고
    • Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis
    • Gottlieb AB, Kang S, Linden KG, et al. Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol 2004;111:28-37
    • (2004) Clin Immunol , vol.111 , pp. 28-37
    • Gottlieb, A.B.1    Kang, S.2    Linden, K.G.3
  • 79
    • 58149271489 scopus 로고    scopus 로고
    • Combining galiximab with the chemotherapeutic agents fludarabine or doxorubicin improves efficacy in animal models of lymphoma
    • Hariharan HK, Murphy T, Clanton D, et al. Combining galiximab with the chemotherapeutic agents fludarabine or doxorubicin improves efficacy in animal models of lymphoma. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;3:3040
    • (2007) ASCO Annual Meeting Proceedings. J Clin Oncol , vol.3 , pp. 3040
    • Hariharan, H.K.1    Murphy, T.2    Clanton, D.3
  • 80
    • 7044255364 scopus 로고    scopus 로고
    • Phase I results from a multicenter trial of galiximab (anti-CD80 antibody, IDEC-114) in combination with rituximab for the treatment of follicular lymphoma [abstract 4951]
    • Gordon LI, Moore JO, Cheson BD, et al. Phase I results from a multicenter trial of galiximab (anti-CD80 antibody, IDEC-114) in combination with rituximab for the treatment of follicular lymphoma [abstract 4951]. Blood 2003;102:307b
    • (2003) Blood , vol.102
    • Gordon, L.I.1    Moore, J.O.2    Cheson, B.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.